BR0313880A - composto, pró-droga, composição farmacêutica, composição e método para modular receptor de cálcio, método para prevenir ou tratar doenças ósseas, e, uso do composto ou um sal deste ou uma pró-droga deste - Google Patents
composto, pró-droga, composição farmacêutica, composição e método para modular receptor de cálcio, método para prevenir ou tratar doenças ósseas, e, uso do composto ou um sal deste ou uma pró-droga desteInfo
- Publication number
- BR0313880A BR0313880A BRPI0313880-1A BR0313880A BR0313880A BR 0313880 A BR0313880 A BR 0313880A BR 0313880 A BR0313880 A BR 0313880A BR 0313880 A BR0313880 A BR 0313880A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- prodrug
- optionally substituted
- salt
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000000651 prodrug Substances 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 208000020084 Bone disease Diseases 0.000 title abstract 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 title abstract 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 229940075993 receptor modulator Drugs 0.000 abstract 1
- 125000005750 substituted cyclic group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40601202P | 2002-08-26 | 2002-08-26 | |
US46612903P | 2003-04-28 | 2003-04-28 | |
PCT/US2003/026317 WO2004017908A2 (en) | 2002-08-26 | 2003-08-21 | Calcium receptor modulating compound and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0313880A true BR0313880A (pt) | 2007-11-06 |
BRPI0313880B1 BRPI0313880B1 (pt) | 2016-09-27 |
BRPI0313880B8 BRPI0313880B8 (pt) | 2021-05-25 |
Family
ID=31949909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0313880A BRPI0313880B8 (pt) | 2002-08-26 | 2003-08-21 | composto |
Country Status (12)
Country | Link |
---|---|
US (3) | US7514441B2 (pt) |
EP (1) | EP1572113B1 (pt) |
JP (1) | JP4494205B2 (pt) |
KR (1) | KR101050700B1 (pt) |
AU (1) | AU2003265585B2 (pt) |
BR (1) | BRPI0313880B8 (pt) |
CA (1) | CA2494700C (pt) |
ES (1) | ES2635838T3 (pt) |
NO (1) | NO332991B1 (pt) |
NZ (1) | NZ538223A (pt) |
PL (1) | PL382706A1 (pt) |
WO (1) | WO2004017908A2 (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101050700B1 (ko) * | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US20090304821A1 (en) * | 2006-03-08 | 2009-12-10 | Takeda Pharmaceutical Company Limited | Pharmaceutical Combination |
WO2007124465A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Stable emulsion formulations |
EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
ES2449340T3 (es) | 2007-03-30 | 2014-03-19 | Amgen Inc. | Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales |
ES2499015T3 (es) * | 2007-05-08 | 2014-09-26 | Ajinomoto Co., Inc. | Agente profiláctico o terapéutico para la diarrea |
RU2516290C2 (ru) | 2007-08-27 | 2014-05-20 | Басф Се | Пиразольные соединения и их использование в способе борьбы с беспозвоночными вредителями, в способе защиты материала размножения растений, в способе лечения или защиты животных от инвазии или инфицирования, в материале размножения растений и сельскохозяйственные композиции, содержащие пиразольные соединения |
EP2202223B1 (en) * | 2007-10-18 | 2017-01-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as blood rbp4 lowering agent |
PL2292592T3 (pl) * | 2008-06-05 | 2013-01-31 | Asahi Kasei Pharma Corp | Związki sulfonamidowe i ich zastosowanie |
KR20110010781A (ko) * | 2008-06-16 | 2011-02-07 | 에프. 호프만-라 로슈 아게 | Nk2 수용체 길항제로서의 피롤리딘 유도체 |
CA2736538C (en) | 2008-09-24 | 2018-02-20 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
WO2010034738A2 (en) * | 2008-09-24 | 2010-04-01 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US8809344B2 (en) | 2008-10-29 | 2014-08-19 | Apath, Llc | Compounds, compositions, and methods for control of hepatitis C viral infections |
US8318759B2 (en) * | 2009-02-18 | 2012-11-27 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives as NK3 receptor antagonists |
WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
WO2011003793A1 (en) | 2009-07-06 | 2011-01-13 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
EP2451804B1 (en) | 2009-07-06 | 2014-04-30 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
CN102469785A (zh) | 2009-07-24 | 2012-05-23 | 巴斯夫欧洲公司 | 防治无脊椎动物害虫的吡啶衍生物 |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012143522A1 (en) * | 2011-04-20 | 2012-10-26 | Glaxo Group Limited | Tetrahydropyrazolo [1,5 -a] pyrimidine as anti -tuberculosis compounds |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
AU2013344716B2 (en) | 2012-11-16 | 2018-03-01 | University Health Network | Pyrazolopyrimidine compounds |
JP6660182B2 (ja) | 2013-03-13 | 2020-03-11 | ジェネンテック, インコーポレイテッド | ピラゾロ化合物及びその使用 |
MX367918B (es) | 2013-04-25 | 2019-09-11 | Beigene Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. |
TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
CN112457403B (zh) | 2013-09-13 | 2022-11-29 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
CN106132967B (zh) | 2014-03-27 | 2019-05-28 | 詹森药业有限公司 | 作为ros1抑制剂的化合物 |
MX367914B (es) | 2014-03-27 | 2019-09-11 | Janssen Pharmaceutica Nv | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1. |
WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
BR112018007664B1 (pt) | 2015-10-16 | 2023-12-19 | Eisai R&D Management Co., Ltd | Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer |
WO2017110881A1 (ja) * | 2015-12-25 | 2017-06-29 | 武田薬品工業株式会社 | 医薬 |
EP3437644B1 (en) * | 2016-03-28 | 2021-06-30 | Takeda Pharmaceutical Company Limited | Compounds for use in the treatment of pulmonary hypertension |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
KR20230162137A (ko) | 2016-08-16 | 2023-11-28 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
CN118252927A (zh) | 2016-08-19 | 2024-06-28 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
WO2018045071A1 (en) | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
TW201831478A (zh) * | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
JP7177043B2 (ja) * | 2017-04-27 | 2022-11-22 | 武田薬品工業株式会社 | 複素環化合物 |
US10919891B2 (en) * | 2017-04-27 | 2021-02-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AU2018290532A1 (en) | 2017-06-26 | 2019-11-21 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
EP3652178B1 (en) | 2017-07-14 | 2024-01-24 | F. Hoffmann-La Roche AG | Bicyclic ketone compounds and methods of use thereof |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
RU2020115915A (ru) | 2017-10-31 | 2021-12-01 | Ф. Хоффманн-Ля Рош Аг | Бициклические сульфоны и сульфоксиды и способы их применения |
JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918074A (en) * | 1984-03-12 | 1990-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Polyazaheterocycle compounds |
EP0217142A3 (en) | 1985-09-30 | 1988-01-07 | Yoshitomi Pharmaceutical Industries, Ltd. | A polyazaheterocyclic compound |
US4746656A (en) | 1986-07-21 | 1988-05-24 | E. R. Squibb & Sons, Inc. | 1,2,4,7-tetrahydro-2-oxopyrazolo[1,5-a]pyrimidine derivatives |
GB9303993D0 (en) * | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
CA2379421A1 (en) | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
DK1257537T3 (da) | 2000-01-24 | 2007-10-01 | Astrazeneca Ab | Terapeutiske morpholino-substituerede forbindelser |
RU2003129060A (ru) | 2001-03-14 | 2005-04-10 | Грюненталь ГмбХ (DE) | Замещенные пиразоло-и тиазолопиримидины |
KR101050700B1 (ko) * | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
-
2003
- 2003-08-21 KR KR1020057003335A patent/KR101050700B1/ko not_active IP Right Cessation
- 2003-08-21 JP JP2004529835A patent/JP4494205B2/ja not_active Expired - Lifetime
- 2003-08-21 CA CA2494700A patent/CA2494700C/en not_active Expired - Lifetime
- 2003-08-21 BR BRPI0313880A patent/BRPI0313880B8/pt not_active IP Right Cessation
- 2003-08-21 US US10/525,158 patent/US7514441B2/en active Active
- 2003-08-21 PL PL382706A patent/PL382706A1/pl not_active Application Discontinuation
- 2003-08-21 WO PCT/US2003/026317 patent/WO2004017908A2/en active Search and Examination
- 2003-08-21 ES ES03793273.8T patent/ES2635838T3/es not_active Expired - Lifetime
- 2003-08-21 NZ NZ538223A patent/NZ538223A/en not_active IP Right Cessation
- 2003-08-21 AU AU2003265585A patent/AU2003265585B2/en not_active Ceased
- 2003-08-21 EP EP03793273.8A patent/EP1572113B1/en not_active Expired - Lifetime
-
2005
- 2005-03-15 NO NO20051328A patent/NO332991B1/no not_active IP Right Cessation
-
2008
- 2008-10-31 US US12/263,426 patent/US20090215746A1/en not_active Abandoned
-
2013
- 2013-11-25 US US14/089,747 patent/US9447100B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20060079536A1 (en) | 2006-04-13 |
NZ538223A (en) | 2008-03-28 |
US20140155416A1 (en) | 2014-06-05 |
AU2003265585B2 (en) | 2008-07-03 |
PL382706A1 (pl) | 2007-11-26 |
CA2494700A1 (en) | 2004-03-04 |
WO2004017908A3 (en) | 2006-01-05 |
US9447100B2 (en) | 2016-09-20 |
US7514441B2 (en) | 2009-04-07 |
JP4494205B2 (ja) | 2010-06-30 |
NO20051328L (no) | 2005-03-15 |
EP1572113A4 (en) | 2006-11-22 |
CA2494700C (en) | 2011-06-28 |
EP1572113A2 (en) | 2005-09-14 |
BRPI0313880B8 (pt) | 2021-05-25 |
JP2006510582A (ja) | 2006-03-30 |
NO332991B1 (no) | 2013-02-11 |
EP1572113B1 (en) | 2017-05-17 |
KR20050038641A (ko) | 2005-04-27 |
US20090215746A1 (en) | 2009-08-27 |
WO2004017908A2 (en) | 2004-03-04 |
AU2003265585A1 (en) | 2004-03-11 |
BRPI0313880B1 (pt) | 2016-09-27 |
ES2635838T3 (es) | 2017-10-05 |
KR101050700B1 (ko) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313880A (pt) | composto, pró-droga, composição farmacêutica, composição e método para modular receptor de cálcio, método para prevenir ou tratar doenças ósseas, e, uso do composto ou um sal deste ou uma pró-droga deste | |
BR0213877A (pt) | Compostos orgânicos | |
BRPI0416004A (pt) | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo | |
BR0312695A (pt) | Derivados de 1h-pirrolidina-2,4-diona espirocìclicos substituìdos por cis-alcóxi | |
BRPI0407283A (pt) | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade | |
BR0108678A (pt) | Novos compostos | |
BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
BRPI0512193A (pt) | entidade quìmica, composição farmacêutica, métodos de tratamento de doença cardìaca, para modular o sarcÈmero cardìaco, e para potencializar miosina cardìaca em um mamìfero, uso de uma entidade quìmica, e, método de preparação de um composto | |
BR9808953A (pt) | Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica | |
BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
BR0110548A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, método de tratamento de distúrbios mediados pelo receptor de neuropeptìdio y5 em um animal de sangue quente, método de tratamento de distúrbios da alimentação em um animal de sangue quente, método para promover perda de peso em um animal de sangue quente, e, uso de um composto ou de um seu sal, prodroga ou solvato farmacêuticamente aceitável | |
PA8575401A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso | |
BRPI0512253A (pt) | composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
DE60132309D1 (de) | Amin-derivate zur behandlung von apoptosis | |
BR0012764A (pt) | Composto, processo para preparar um composto, composição farmacêutica, uso de um composto e método de tratar um paciente humano ou animal | |
BR0102607A (pt) | Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos | |
BRPI0408767A (pt) | inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv | |
BRPI0409241A (pt) | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso | |
BRPI0410979A (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia | |
BR0316690A (pt) | Composto, prodroga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
BRPI0414780B8 (pt) | composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto | |
BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 31/00, A61K 31/473, A61K 31/519, A61K 31/53, A61K 31/551, C07D 221/04, C07D 471/04, C07D 487/04, A61P 19/08 Ipc: C07D 221/04 (2011.01), C07D 487/04 (2011.01), C07D |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 221/04 , C07D 487/04 , C07D 471/04 , A61K 31/519 , A61K 31/473 , A61K 31/551 , A61K 31/53 Ipc: A61K 31/00 (2006.01), A61K 31/473 (2006.01), A61K |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/09/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2788 DE 11/06/2024 POR TER SIDO INDEVIDA. |